A. Company Profile

Millennium (NASDAQ:MLNM) is one of the world's leading biotech companies. The company's product portfolio includes innovative treatments across a wide range of therapeutic areas. There are extensive discovery and development programs in the field of oncology at Millennium.

B. Products

Product Pipelines

Product

Indication

Clinical Status

Campath

B-cell chronic lymphocytic leukemia

Market

MLN518

Acute myeloid leukemia

Phase I

MLN8054

Various tumors

Phase I

Velcade

Multiple myeloma

Market

Various tumors

Phase I-III

1.Campath

Campath is indicated for the treatment of B-cell chronic lymphocytic leukemia (B-CLL) in patients who have been treated with alkylating agents and who have failed fludarabine therapy.

2. MLN 518

MLN518 is a small molecule specifically designed to inhibit the fms-like tyrosine kinase-3 (FLT-3) receptor tyrosine kinase in patients with acute myeloid leukemia (AML).

3. MLN8054

MLN8054 is a novel small molecule Aurora A kinase inhibitor. Aurora kinases are required for cells to proceed through mitosis (cell division) and are over-expressed in a variety of cancers and therefore represent an attractive group of oncology therapeutic targets.

4. Velcade

Velcade is an anti-cancer agent known as proteasome inhibitors.